Anzeige
Mehr »
Mittwoch, 29.10.2025 - Börsentäglich über 12.000 News
Die 80-Milliarden-Dollar-Nuklear-Renaissance: Warum Uran der heißeste Sektor der Welt ist
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40VVS | ISIN: US64136E1029 | Ticker-Symbol:
NASDAQ
29.10.25 | 17:37
4,720 US-Dollar
+0,21 % +0,010
Branche
Biotechnologie
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
NEUPHORIA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
NEUPHORIA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur NEUPHORIA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoNeuphoria führt nach Aktien-Akkumulation Aktionärsrechtsplan ein6
MoNeuphoria adopts stockholder rights plan following share accumulations1
MoNeuphoria Therapeutics, Inc.: Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process56BURLINGTON, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (Nasdaq: NEUP), a clinical-stage biotechnology company developing impactful treatments...
► Artikel lesen
MoNeuphoria Therapeutics Inc. - 8-K, Current Report12
21.10.Neuphoria nixes social anxiety program and starts strategic review after phase 3 flop11
21.10.Morning Market Movers: AlphaVest Acquisition Corp., Neuphoria Therapeutics, BranchOut Food, rYojbaba See Big Swings595BEIJING (dpa-AFX) - At 7:35 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening...
► Artikel lesen
20.10.Neuphoria stock plunges after failed anxiety disorder drug trial8
NEUPHORIA THERAPEUTICS Aktie jetzt für 0€ handeln
20.10.Gescheiterte Medikamentenstudie: Neuphoria-Aktie bricht um 67,1 % ein18
20.10.Neuphoria's anxiety drug fails in late-stage trial, shares tumble1
20.10.Neuphoria Therapeutics, Inc.: Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder599AFFIRM-1 trial did not meet primary endpoint or secondary endpoints Company to conduct strategic review of portfolio and business operations BURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria...
► Artikel lesen
30.09.Neuphoria Therapeutics Inc. Full Year Loss Drops5
29.09.Neuphoria schließt Phase-3-Studie zu sozialer Angststörung ab: Top-Line-Daten Anfang Q4 2025 erwartet5
29.09.Neuphoria completes patient visits in phase 3 social anxiety trial1
29.09.Neuphoria Therapeutics, Inc.: Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates260Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout anticipated in early Q4 2025 Cash runway extended through fiscal...
► Artikel lesen
29.09.Neuphoria Therapeutics Inc. - 10-K, Annual Report4
16.09.Neuphoria Therapeutics Inc. - 8-K, Current Report7
05.09.Pressmaster DMCC: One of the World's Largest Remote EEG Studies Begins: Neuphoria Partners with Monroe Institute513Brisbane, Australia--(Newsfile Corp. - September 5, 2025) - Neuphoria and the Monroe Institute announced the launch of an IRB-approved remote brainwave analysis research project involving 333 participants....
► Artikel lesen
04.09.Neuphoria Therapeutics, Inc.: Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)263BURLINGTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) ("Neuphoria" or the "Company"), a clinical-stage biotechnology company developing impactful treatments...
► Artikel lesen
18.07.Neuphoria Therapeutics Inc. - 8-K, Current Report15
27.05.Neuphoria Therapeutics, Inc.: Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting10
Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1